Xiamen University Affiliated Xiamen Eye Center, Eye Institute of Xiamen University, School of Medicine, Xiamen University, Xiamen 361102, China; Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, Fujian Engineering and Research Center of Eye Regenerative Medicine, Xiamen 361102, China.
Department of Interventional Radiology, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian 361000, China.
J Control Release. 2024 Oct;374:50-60. doi: 10.1016/j.jconrel.2024.08.002. Epub 2024 Aug 9.
Corneal neovascularization (CNV) is a major cause of blindness worldwide. However, the recent drug treatment is limited by repeated administration and low drug bioavailability. In this work, SU6668 (an inhibitor of receptor tyrosine kinases) and indocyanine green (ICG) are loaded onto poly(lactic-co-glycolic acid) (PLGA) nanoparticles, and then coated with anti-VEGFR2 single chain antibody (AbVr2 scFv) genetically engineered cell membrane vesicles. The nanomedicine is delivered via eye drops, and the hyperthermia induced by laser irradiation could block the blood vessels. Meanwhile, the photothermal effect can also cause the degradation of nanomaterials and release chemotherapeutic drugs in the blocked area, thereby continuously inhibit the neovascularization. Furthermore, SU6668 could inhibit the expression of heat shock protein 70 (HSP70), promoting the cell death induced by photothermal effect. In conclusion, the combination of photothermal and chemotherapy drugs provides a novel, effective and safe approach for the treatment of CNV.
角膜新生血管（CNV）是全球范围内导致失明的主要原因。然而，最近的药物治疗受到重复给药和低药物生物利用度的限制。在这项工作中，SU6668（受体酪氨酸激酶抑制剂）和吲哚菁绿（ICG）被装载到聚（乳酸-共-乙醇酸）（PLGA）纳米颗粒上，然后用抗血管内皮生长因子受体 2 单链抗体（AbVr2 scFv）基因工程细胞膜囊泡进行包被。该纳米药物通过滴眼剂给药，激光照射引起的热疗可以阻断血管。同时，光热效应还可以导致纳米材料的降解，并在阻塞区域释放化疗药物，从而持续抑制新生血管形成。此外，SU6668 可以抑制热休克蛋白 70（HSP70）的表达，促进光热效应诱导的细胞死亡。总之，光热和化疗药物的联合为治疗 CNV 提供了一种新颖、有效和安全的方法。
